Year None202420232022202120202019201820172016 November 15, 2024 Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update Go to November 13, 2024 Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS) Go to November 11, 2024 Medicenna Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (pembrolizumab) at the 39th Annual Meeting of SITC Go to November 8, 2024 Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Go to October 4, 2024 Medicenna to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Go to September 26, 2024 Medicenna Announces Results of Annual Meeting of Shareholders Go to Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Next page next › Last page last »
November 15, 2024 Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update Go to
November 13, 2024 Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS) Go to
November 11, 2024 Medicenna Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (pembrolizumab) at the 39th Annual Meeting of SITC Go to
November 8, 2024 Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Go to
October 4, 2024 Medicenna to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Go to
